Inflammation

Many acute, intermittent and chronic auto-immune and inflammatory diseases are characterized by a TF-driven up-regulation of critical cytokines and chemokines, which set off a cascade of biological events leading to irreversible tissue damage. Most current therapies target a single cytokine in an attempt to down-regulate its expression and slow down the inflammatory response. This strategy has had success in limiting damage for many patients; however, substantial unmet need remains. Targeting Tissue Factor opens the possibility of simultaneously modulating the expression of multiple cytokines and chemokines to help restore homeostasis. In preclinical experiments, we have shown this effect in well-established disease models of several disease states. We intend to take our most advanced programs into clinical trials in both acute settings as well as in chronic diseases.